CClinicalTrials.gg
Status unknownNCT05355480HANDWRMLUpdated Mar 23, 2023

Handwriting Analysis in Movement Disorders

An observational study in Movement Disorders, Parkinson Disease and Writing Disorder, sponsored by Neuromed IRCCS. Status unknown at 1 site in Italy. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-23.

Sponsored by Neuromed IRCCS · Observational

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Handwriting is a complex cognitive prowess that deteriorates in patients affected by neurodegenerative diseases, including movement disorders. More in detail, patients with Parkinson's disease (PD) may manifest prominent handwriting abnormalities which have been collectively identified as parkinsonian micrographia. MIcrographia may manifest at the onset of the disease and then worsens progressively with time. Previous techniques released to investigate micrographia in PD relied on perceptual analysis of simple tasks or were based on expensive technological tools, including tablets. However, handwriting can be promptly collected in an ecological scenario, through safe, cheap, and largely available tools. Also, the objective handwriting analysis through artificial intelligence would represent an innovative strategy even superior to previous techniques, since it allows for the analysis of large amounts of data. In this experimental project, the investigators apply a specific machine learning algorithm to analyze handwriting samples recorded in healthy controls and PD patients. The study aims to verify whether the technique proposed by the investigators would be able to detect parkinsonian micrographia objectively, monitor the evolution of handwriting abnormalities and assess the symptomatic improvement of handwriting following L-Dopa administration in PD patients.

02

Conditions studied

  • Movement Disorders
  • Parkinson Disease
  • Writing Disorder
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's planned enrollment of 40 is below the median of 96 across 1,057 observational studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Neuromed IRCCS is the lead sponsor of 76 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy subjects and patients with idiopathic PD

Inclusion criteria

  • Healthy conditions
  • clinical diagnosis of Parkinson's disease

Exclusion criteria

Exclusion Criteria:

  • cognitive decline
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Healthy Subjects

    Collection of handwriting samples

  • Patients with Parkinson's disease

    Collection of handwriting samples

06

What researchers measure

Primary outcomes

  1. Stroke size of handwriting characters

    height of single letters

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • IRCCS Neuromed
    Pozzilli, 86077, Italy
    • Antonio Suppa, MD · Contact · +00390649914074
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05355480
Lead sponsor
Neuromed IRCCS
Responsible party
Antonio Suppa (Prof., Neuromed IRCCS) — Principal investigator
First posted
May 2, 2022
Start date
Dec 1, 2022
Primary completion
Dec 31, 2022
Completion
Dec 31, 2023 (estimated)
Last update
Mar 23, 2023

Study contacts

Antonio Suppa, MD
Contact
antonio.suppa@uniroma1.it
+00390649914074

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion